| Literature DB >> 28664413 |
Tariq Al-Zaid1, Wei-Lien Wang2,3,4, Neeta Somaiah5, Alexander J Lazar6,7,8.
Abstract
Sarcoma is a large and heterogeneous group of malignant mesenchymal neoplasms with significant histological overlap. Accurate diagnosis can be challenging yet important for selecting the appropriate treatment approach and prognosis. The currently torrid pace of new genomic discoveries aids our classification and diagnosis of sarcomas, understanding of pathogenesis, development of new medications, and identification of alterations that predict prognosis and response to therapy. Unfortunately, demonstrating effective targets for precision oncology has been elusive in most sarcoma types. The list of potential targets greatly outnumbers the list of available inhibitors at the present time. This review will discuss the role of molecular profiling in sarcomas in general with emphasis on selected entities with particular clinical relevance.Entities:
Keywords: Immune checkpoint inhibitors; Immunotherapy; Molecular diagnostics; Next generation sequencing (NGS); Sarcoma; Targeted therapy
Mesh:
Substances:
Year: 2017 PMID: 28664413 DOI: 10.1007/s00428-017-2174-3
Source DB: PubMed Journal: Virchows Arch ISSN: 0945-6317 Impact factor: 4.064